Jay McLaughlin

Optimized REV-ERB agonists for Chronic Inflammatory Pain

Development of negative allosteric modulators at the mu opioid receptor

Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat & cocaine

Theranostic CAR-T Targeting Senescence in Alzheimer's

Development of SBS-226, a MOR agonist / DOR antagonist, for OUD

Novel cyclic peptide analgesics for intranasal delivery

Molecularmechanisms:DysregulationofmonoaminetransportersbyHIV-1TatandcocainePO2000079156/USC10014420

Efficacy and signaling modulation by targeting the sodium site at mu opioid receptor

Targeting the allosteric sodium site with novel probes for delta opioid receptor

Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder

Cyclic Peptides to Treat Cocaine Use Disorder

EVALUATION OF NOVEL COMPOUNDS POTENTIALLY TARGETING CENTRAL SIGMA RECEPTORS REGARDING THEIR ABILITY TO LOWER BLOOD GLUCOSE IN DIABETIC MICE.

Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder

Function of astrocytes autophagy in brain homeostasis and opioid-induced maladaptive behavior and addiction, in the context of HIV

Cyclic Peptides to Treat Cocaine Use Disorder

Impacts of morphine and HIV-Tat exposures and dimethylfumarate treatment on brain BDNF and mitochondrial and behavioral dysfunction.

In vivo characterization of bitopic cyclic ligands and analogs.

Evaluation of novel compounds potentially targeting central sigma receptors using both in vivo and in vitro assays

Sparian Biosciences - McLaughlin

Pharmacological probes based on mitragynine pseudoindoxyl.

Therapeutic and mechanistic evaluation of multifunctional opioids as improved treatments for pain and substance abuse

Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects

Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine.